Addition of Ipragliflozin to Metformin Treatment in Korean Patients with Type 2 Diabetes Mellitus: Subgroup Analysis of a Phase 3 Trial-Reference-Cited by-同舟云学术

Addition of Ipragliflozin to Metformin Treatment in Korean Patients with Type 2 Diabetes Mellitus: Subgroup Analysis of a Phase 3 Trial

Published:2017 Issue:2 Volume:41 Page:135
ISSN:2233-6079
Container-title:Diabetes & Metabolism Journal
language:en
Short-container-title:Diabetes Metab J

Author:

Min Kyung-Wan¹,Ku Bon Jeong²,Lee Ji-Hyun³,Kim Min-Seon⁴,Ahn Kyu-Jeung⁵,Lee Moon-Kyu⁶,Kokubo Satoshi⁷,Yoshida Satoshi⁷,Cho Hyun-Ji⁸,Cha Bong-Soo⁹^ORCID

Affiliation:

1. Department of Internal Medicine, Eulji General Hospital, Eulji University School of Medicine, Seoul, Korea.

2. Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, Korea.

3. Department of Internal Medicine, Catholic University of Daegu School of Medicine, Daegu, Korea.

4. Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Ulsan College of Medicine, Seoul, Korea.

5. Department of Endocrinology and Metabolism, Kyung Hee University Hospital at Gangdong, Kyung Hee University Medical Center, Seoul, Korea.

6. Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

7. Astellas Pharma Inc., Tokyo, Japan.

8. Astellas Korea Inc., Seoul, Korea.

9. Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.

Funder

Astellas Pharma Inc.

Publisher

Korean Diabetes Association

Subject

Endocrinology, Diabetes and Metabolism

Link

https://synapse.koreamed.org/pdf/10.4093/dmj.2017.41.2.135

Reference24 articles.

1. The Epidemiology of Diabetes in Korea

2. Clinical characteristics of Korean type 2 diabetic patients in 2005

3. β-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of ipragliflozin on liver enzymes in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials;Expert Opinion on Pharmacotherapy;2024-05-02

2. Effects of sodium-glucose cotransporter 2 inhibitors on bone metabolism in patients with type 2 diabetes mellitus: a systematic review and meta-analysis;BMC Endocrine Disorders;2024-04-24

3. Add-on therapy with dapagliflozin in routine outpatient care of type 2 diabetes patients from Turkey: a retrospective cohort study on HbA1c, body weight, and blood pressure outcomes;International Journal of Diabetes in Developing Countries;2021-05-04

SGLT2 Inhibitors as Add-On Therapy to Metformin for People with Type 2 Diabetes: A Review of Placebo-Controlled Trials in Asian versus Non-Asian Patients

;Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy;2020-08

5. Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial;Journal of Clinical Medicine;2020-01-18